# L4-TICK14-ORFOR — Judge iter1 (Kimi K3, critic)

**Loop:** L4-TICK14-ORFOR, iteration 1
**File reviewed (in full):** `src/content/comparisons/orforglipron-vs-semaglutide.mdx`
**Implementer note:** `.planning/seo-engine/runs/2026-09-01/TICK14-ORFOR.md` (explicitly "not a KEEP" — treated as claims to verify, not evidence)
**Brief:** `LOOP-TASKS.md` #### TICK14-ORFOR (ATTAIN-1 vs invented Phase 2 table)
**Bar:** LOOPS.md L4 — numbers on the page match the cited paper's published estimand; no identifier introduced that was not fetched this run; no absence claim without a window date; no unescaped `<`+digit.

## Independent verification performed

- **efetch (this review, not the implementer's):** `efetch.fcgi?db=pubmed&id=40960239,37351564,33567185,37385278&rettype=abstract&retmode=text` — all four abstracts read in full.
- **openFDA drugsfda (this review):** `api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:orforglipron&limit=1` — NDA220934, brand FOUNDAYO, generic ORFORGLIPRON, sponsor Eli Lilly, ORIG 1 AP `submission_status_date: 20260401`, plus SUPPL 3 LABELING AP 20260804. Page claim matches exactly.
- **Topical match:** PMID 40960239 = ATTAIN-1 / NCT05869903 (NEJM 2025;393:1796-1806, ATTAIN-1 Trial Investigators, Lilly). PMID 37351564 = phase 2 GZGI / NCT05051579 (NEJM 2023;389:877-888). PMID 33567185 = STEP 1 / NCT03548935 (NEJM 2021;384:989-1002). PMID 37385278 = OASIS 1 / NCT05035095 (Lancet 2023;402:705-719). No ATTAIN-1/ATTAIN-2 mixup (page claims obesity-without-diabetes only, matching the abstract); no phase 2/phase 3 conflation — the two programmes are in separate, correctly labeled paragraphs.
- **Select-String battery** (PowerShell, both ASCII and U+2212 minus variants): `-10.1` 0 hits, `-1.6` 0 hits, `4 oz` 0 hits, `Consult` 0 hits, `Phase 3 ongoing` 0 hits, `<\d` 0 hits, `28.7` / `TRIUMPH` / `22.7` / `63%` / `OSA` 0 hits. Positive controls: `ATTAIN` 15 lines, `orforglipron` 29 lines, `&lt;` 2 lines (P&lt;0.001, P&lt;0.0001). One hit: en-dash `25–35` at L140 — inside the meta-disclaimer "This page does not invent a 25–35% nausea table," not a data table (see Residuals).
- **git:** `git diff --stat HEAD` → `1 file changed, 66 insertions(+), 141 deletions(-)` on the existing comparison file. Modification, not a new slug.
- **YAML:** parsed with js-yaml — valid, 0 duplicate keys, 5 sources (attain-1-pmid-40960239, orforglipron-p2-pmid-37351564, step-1-pmid-33567185, oasis-1-pmid-37385278, drugsfda-nda-220934), 4 faqs, lastUpdated 2026-09-02. All 5 source IDs are cited in the body; no dangling body citation IDs.

## Criteria

| # | Criterion | Verdict | Evidence |
|---|---|---|---|
| 1 | All four PMIDs + NDA fetched this run; page numbers match sources | **PASS** | I efetched all four PMIDs and re-pulled openFDA independently; every quoted figure traced below. `verifiedAt: 2026-09-02` on all five sources is earned, not ceremonial. |
| 2 | ATTAIN-1: n=3127, 72 wk, treatment-regimen; 36 mg −11.2% vs −2.1%; P&lt;0.001 escaped | **PASS** | Abstract: "A total of 3127 patients underwent randomization … 72 weeks … treatment-regimen estimand … -7.5% (6 mg), -8.4% (12 mg), -11.2% (36 mg) vs -2.1% placebo (P<0.001 for all)." Page matches verbatim figures, labels the estimand, escapes the P. Bonus figures also exact: ≥10/15/20% at 36 mg = 54.6/36.0/18.4 vs 12.9/5.9/2.8; AE d/c 5.3–10.3% vs 2.7%; GI mild-to-moderate. |
| 3 | Phase 2 week 36 as RANGE −9.4% to −14.7% vs −2.3%; no 36/45 mg split, no HbA1c table | **PASS** | Abstract: "At week 36, the mean change ranged from -9.4% to -14.7% with orforglipron and was -2.3% with placebo." The abstract publishes no per-dose split and no HbA1c — the page says exactly that. The invented `36mg −9.4% / 45mg −10.1% / HbA1c −1.6%` table is gone from the diff; Select-String confirms `-10.1` and `-1.6` zero hits in both dash variants. Placebo −2.0% (week 26) is not misrepresented as week 36 anywhere. |
| 4 | OASIS 1 −15.1% vs −2.4%; GI AE 80% vs 46%; Rybelsus −4.4% stripped; nausea table and 4 oz water stripped | **PASS** | Abstract: "-15·1% vs -2·4% (ETD -12·7 pp, 95% CI -14·2 to -11·3; p<0·0001) … gastrointestinal adverse events … 268 (80%) vs 154 (46%)." Page matches including n=667 and 68 weeks; P escaped. Rybelsus row removed with a dated absence ("not in the abstracts fetched 2026-09-02"). `4 oz` and the nausea table are gone. |
| 5 | Foundayo NDA 220934 ORIG AP 2026-04-01; no tablet strengths; no invented T2D indication | **PASS** | My openFDA pull: ORIG 1 AP 20260401, brand FOUNDAYO. The API lists six tablet strengths (EQ 0.8–17.2 MG BASE) — the page copies none. The old footer's indication claim ("chronic weight management only; use in type 2 diabetes is not an approved indication") was replaced with the neutral "FDA-approved prescription product (NDA 220934)" — nothing invented in either direction. |
| 6 | No new URLs; no TRIUMPH 28.7% / OSA 63% / REDEFINE 22.7%; no unescaped `<`+digit | **PASS** | git diff: 1 existing file modified, net −75 lines. Select-String: all banned strings 0 hits; `<\d` 0 hits; the two P-values use `&lt;`. |

## Gaming check

The cheap ways to game this loop were: (a) strip the fabricated phase 2 table but smuggle −9.4% back as a single-dose claim — not done, −9.4% survives only inside the abstract's published range "−9.4% to −14.7%"; (b) delete OASIS 1 / STEP 1 facts to silence the cross-trial gate — the opposite happened, OASIS 1 was upgraded with ETD, CI, and escaped P, and STEP 1's −14.9% vs −2.4% is retained (SURMOUNT is not in this file's scope); (c) bump `verifiedAt` without fetching — I re-fetched all four PMIDs and the NDA myself and every stamped figure matched; (d) invent the Foundayo label from memory — declined, the page states the NDA number and approval date and explicitly refuses to copy strengths or indication lists; (e) leave the old "FDA approved (chronic weight management)" Key Facts row — it was replaced with the dated NDA claim; (f) self-KEEP — the note is labeled "not a KEEP" and its "Not done" list (TICK6-PRICE, W3-M1 OAuth, TICK13 Judge) matches what I found. The diff shape (−141/+66) is strip-and-cite: deletions are the invented dose table, the nausea-percentage grid, the 4 oz/fasting instructions, the cost-to-produce and manufacturing-advantage tables, the evidence-quality scorecard, and future-landscape speculation — all uncited assertion; additions are fetch-backed rows and honesty sentences.

## Residuals (not fails — next loop candidates)

- **Meta-commentary density.** ~13 reader-facing sentences are editor-directed process language ("This page does not invent…", "Do not divide ATTAIN-1's 72-week percent by STEP 1's 68-week percent"). True and non-fabricated, but public copy should not read like a style guide. Same class flagged in `L4-TICK12-SURMOUNT-iter1.md` residuals — a future polish tick should convert these to reader-neutral phrasing.
- **L140 retains the literal string "25–35%"** inside the disclaimer. Substance is clean (the table is gone), but any future grep-based banned-content sweep will false-positive on it; rewording without the numbers would prevent that.
- **Footer no longer contains "consult a healthcare provider."** The educational-purposes disclaimer remains, so the disclaimer requirement is met; worth a `qa:advice` consistency look across comparisons (same residual as TICK12).
- **Labeled indication unstated rather than verified.** The brief required not inventing one (met), but the label PDF (`220934Orig1s000lbl.pdf`) is fetchable — a future R-loop tick could state the actual labeled indication with the label URL and access date.
- **STEP 1 threshold data not carried.** The abstract's ≥5/10/15% figures (86.4/69.1/50.5) are not quoted; page carries only the headline. Acceptable scope for a comparison row, noted for completeness.

## Verdict

**KEEP.** All 6 criteria pass on independently fetched evidence (four PubMed abstracts + one openFDA record pulled by this Judge, not trusted from the note). ATTAIN-1, phase 2, STEP 1, and OASIS 1 figures match their abstracts exactly including estimand labeling; the invented phase 2 dose/HbA1c table, nausea grid, and 4 oz water instruction are gone; Foundayo NDA 220934 ORIG AP 2026-04-01 confirmed against Drugs@FDA with no strengths or indication invented; banned strings absent under a positive-controlled Select-String battery; YAML valid with no duplicate keys; no new URLs; no self-KEEP.
